NCT07723703
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07723703
Title Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML (BRAMLIE)
Acronym BRAMLIE
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amphista Therapeutics Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.